IDiyas

For the Inventor, By the Inventor

Lexington, MA, United States of America

Jing Li

USPTO Granted Patents = 18 

 

Average Co-Inventor Count = 4.6

ph-index = 4

Forward Citations = 62(Granted Patents)


Location History:

  • Massachusetts, MA (US) (2021)
  • Gaithersburg, MD (US) (2021 - 2022)
  • Lexington, MA (US) (2009 - 2023)

Company Filing History:

goldMedal6 out of 541 
 
Medimmune Limited
 patents
silverMedal4 out of 1,309 
 
Wyeth
 patents
bronzeMedal4 out of 18 
 
Wuxi Biologics Ireland Limited
 patents
4. 3 out of 5 
 
Wuxi Biologics (shanghai) Co., Ltd.
 patents
5. 2 out of 2 
 
Wuxi Biologies (shanghai) Co., Ltd.
 patents
6. 2 out of 1,970 
 
Amgen Inc.
 patents
7. 1 out of 389 
 
Genetics Institute, Inc.
 patents
8. 1 out of 3,923 
 
Novartis Ag
 patents
9. 1 out of 3 
 
Wuxi Biologies Ireland Limited
 patents
10. 1 out of 8 
 
Cstone Pharmaceuticals
 patents
11. 1 out of 5 
 
Cstone Pharmaceuticals (suzhou) Co., Ltd.
 patents
12. 1 out of 7 
 
Cstone Pharmaceuticals (shanghai) Co., Ltd.
 patents
13. 1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2009-2025

where 'Filed Patents' based on already Granted Patents

18 patents (USPTO):
1. 12240906 - Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (2025-03-04),
2. 12180282 - Anti-PD-L1 antibodies (2024-12-31),
3. 11643465 - Anti-PD-1 antibodies (2023-05-09),
4. 11643463 - Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (2023-05-09),
5. 11414487 - Monoclonal antibodies to programmed death 1 (PD-1) (2022-08-16),
6. 11220541 - CCL20 as a predictor of clinical response to IL23-antagonists (2022-01-11),
7. 11111313 - Anti-PCSK9 antibodies (2021-09-07),
8. 11078281 - Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (2021-08-03),
9. 11016099 - Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers (2021-05-25),
10. 11008391 - Anti-PD-1 antibodies (2021-05-18),
11. 10981995 - Anti-PD-L1 antibodies (2021-04-20),
12. 10696745 - Anti-PD-L1 antibodies (2020-06-30),
13. 9120855 - Biologic compounds directed against death receptor 5 (2015-09-01),
14. 8470993 - Nucleic acid encoding antibody to human IL-22 (2013-06-25),
15. 8187603 - Antibodies to human IL-22 (2012-05-29),

Title: The Innovative Journey of Jing Li

Introduction: Jing Li, a pioneering inventor based in Lexington, MA, has made significant contributions to the field of technology with her groundbreaking innovations.

Latest Patents: Jing Li holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing her diverse range of expertise and forward-thinking approach to problem-solving.

Career Highlights: With a background in engineering and a passion for creating solutions that make a difference, Jing Li has led successful projects that have revolutionized industries and improved the lives of many.

Collaborations: Throughout her career, Jing Li has collaborated with top research institutions, leading companies, and brilliant minds in the field, fostering a culture of innovation and excellence in all her endeavors.

Conclusion: Jing Li's relentless pursuit of innovation and her commitment to pushing the boundaries of what is possible make her a true trailblazer in the world of inventions. Her work continues to inspire and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…